Literature DB >> 11423995

c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.

B Jiménez1, O V Volpert, F Reiher, L Chang, A Muñoz, M Karin, N Bouck.   

Abstract

Thrombospondin-1 (TSP-1) is a potent inhibitor of angiogenesis that acts directly on endothelial cells via the CD36 surface receptor molecule to halt their migration, proliferation, and morphogenesis in vitro and to block neovascularization in vivo. Here we show that inhibitory signals elicited by TSP-1 did not alter the ability of inducers of angiogenesis to activate p42 and p44 mitogen-activated protein kinase (MAPK). Rather, TSP-1 induced a rapid and transient activation of c-Jun N-terminal kinases (JNK). JNK activation by TSP-1 required engagement of CD36, as it was blocked by antagonistic CD36 antibodies and stimulated by short anti-angiogenic peptides derived from TSP-1 that act exclusively via CD36. TSP-1 inhibition of corneal neovascularization induced by bFGF was severely impaired in mice null for JNK-1, pointing to a critical role for this stress-activated kinase in the inhibition of neovascularization by TSP-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423995     DOI: 10.1038/sj.onc.1204464

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  FGF-2- and TGF-β1-induced downregulation of lumican and keratocan in activated corneal keratocytes by JNK signaling pathway.

Authors:  Jian Chen; Julie Wong-Chong; Nirmala SundarRaj
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-21       Impact factor: 4.799

2.  G protein-coupled receptor signaling through Gq and JNK negatively regulates neural progenitor cell migration.

Authors:  Norikazu Mizuno; Hiroshi Kokubu; Maiko Sato; Akiyuki Nishimura; Junji Yamauchi; Hitoshi Kurose; Hiroshi Itoh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

3.  Commentary on Myers et al.: growing role of the innate immunity receptor CD36 in central nervous system diseases.

Authors:  Lidia Garcia-Bonilla; Laibaik Park; Costantino Iadecola
Journal:  Exp Neurol       Date:  2014-08-23       Impact factor: 5.330

Review 4.  Thrombospondins in the transition from myocardial infarction to heart failure.

Authors:  Jonathan A Kirk; Oscar H Cingolani
Journal:  J Mol Cell Cardiol       Date:  2015-12-10       Impact factor: 5.000

Review 5.  Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.

Authors:  Patrick R Lawler; Jack Lawler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

6.  Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.

Authors:  Shideh Kazerounian; Mark Duquette; Millys A Reyes; James T Lawler; Keli Song; Carole Perruzzi; Luca Primo; Roya Khosravi-Far; Federico Bussolino; Isaac Rabinovitz; Jack Lawler
Journal:  Blood       Date:  2011-03-04       Impact factor: 22.113

Review 7.  Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

Authors:  Tanya A Rege; Constance Y Fears; Candece L Gladson
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 8.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Authors:  Y Mirochnik; A Kwiatek; O V Volpert
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

9.  Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-mediated signaling.

Authors:  Irina N Baranova; Roger Kurlander; Alexander V Bocharov; Tatyana G Vishnyakova; Zhigang Chen; Alan T Remaley; Gyorgy Csako; Amy P Patterson; Thomas L Eggerman
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Thrombospondin 1 Suppresses Insulin Signaling in C2C12 Myotubes.

Authors:  Kaku Matsugi; Tetsuya Hosooka; Kazuhiro Nomura; Wataru Ogawa
Journal:  Kobe J Med Sci       Date:  2016-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.